These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
372 related articles for article (PubMed ID: 20807681)
1. Intensive glucose control and cardiovascular outcomes in type 2 diabetes. Macisaac RJ; Jerums G Heart Lung Circ; 2011 Oct; 20(10):647-54. PubMed ID: 20807681 [TBL] [Abstract][Full Text] [Related]
2. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. Bonds DE; Miller ME; Bergenstal RM; Buse JB; Byington RP; Cutler JA; Dudl RJ; Ismail-Beigi F; Kimel AR; Hoogwerf B; Horowitz KR; Savage PJ; Seaquist ER; Simmons DL; Sivitz WI; Speril-Hillen JM; Sweeney ME BMJ; 2010 Jan; 340():b4909. PubMed ID: 20061358 [TBL] [Abstract][Full Text] [Related]
3. Pharmacologic prevention of microvascular and macrovascular complications in diabetes mellitus: implications of the results of recent clinical trials in type 2 diabetes. Tandon N; Ali MK; Narayan KM Am J Cardiovasc Drugs; 2012 Feb; 12(1):7-22. PubMed ID: 22217193 [TBL] [Abstract][Full Text] [Related]
4. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus. Plosker GL; Figgitt DP Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124 [TBL] [Abstract][Full Text] [Related]
5. Diabetes and Cardiovascular Disease: Is intensive glucose control beneficial or deadly? Lessons from ACCORD, ADVANCE, VADT, UKPDS, PROactive, and NICE-SUGAR. Schernthaner G Wien Med Wochenschr; 2010 Jan; 160(1-2):8-19. PubMed ID: 20229156 [TBL] [Abstract][Full Text] [Related]
6. Intensive glycemic control and cardiovascular disease: an update. Brown A; Reynolds LR; Bruemmer D Nat Rev Cardiol; 2010 Jul; 7(7):369-75. PubMed ID: 20404853 [TBL] [Abstract][Full Text] [Related]
7. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. Meier M; Hummel M Vasc Health Risk Manag; 2009; 5():859-71. PubMed ID: 19898642 [TBL] [Abstract][Full Text] [Related]
8. Megatrials in type 2 diabetes. From excitement to frustration? Del Prato S Diabetologia; 2009 Jul; 52(7):1219-26. PubMed ID: 19373446 [TBL] [Abstract][Full Text] [Related]
9. Improvement of glycemic control in type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials. Monami M; Candido R; Pintaudi B; Targher G; Mannucci E; Nutr Metab Cardiovasc Dis; 2021 Aug; 31(9):2539-2546. PubMed ID: 34158243 [TBL] [Abstract][Full Text] [Related]
10. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. Miller ME; Bonds DE; Gerstein HC; Seaquist ER; Bergenstal RM; Calles-Escandon J; Childress RD; Craven TE; Cuddihy RM; Dailey G; Feinglos MN; Ismail-Beigi F; Largay JF; O'Connor PJ; Paul T; Savage PJ; Schubart UK; Sood A; Genuth S; BMJ; 2010 Jan; 340():b5444. PubMed ID: 20061360 [TBL] [Abstract][Full Text] [Related]
11. Post-trial monitoring of a randomised controlled trial of intensive glycaemic control in type 2 diabetes extended from 10 years to 24 years (UKPDS 91). Adler AI; Coleman RL; Leal J; Whiteley WN; Clarke P; Holman RR Lancet; 2024 Jul; 404(10448):145-155. PubMed ID: 38772405 [TBL] [Abstract][Full Text] [Related]
12. What matters in ADVANCE and ADVANCE-ON. Hamet P Diabetes Obes Metab; 2012 Jan; 14 Suppl 1():20-9. PubMed ID: 22118707 [TBL] [Abstract][Full Text] [Related]
13. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. Boussageon R; Bejan-Angoulvant T; Saadatian-Elahi M; Lafont S; Bergeonneau C; Kassaï B; Erpeldinger S; Wright JM; Gueyffier F; Cornu C BMJ; 2011 Jul; 343():d4169. PubMed ID: 21791495 [TBL] [Abstract][Full Text] [Related]
14. Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. van der Leeuw J; Visseren FL; Woodward M; van der Graaf Y; Grobbee DE; Harrap S; Heller S; Mancia G; Marre M; Poulter N; Zoungas S; Chalmers J Diabetologia; 2016 Dec; 59(12):2603-2612. PubMed ID: 27586250 [TBL] [Abstract][Full Text] [Related]
15. Glucose supply and insulin demand dynamics of antidiabetic agents. Monte SV; Schentag JJ; Adelman MH; Paladino JA J Diabetes Sci Technol; 2010 Mar; 4(2):365-81. PubMed ID: 20307399 [TBL] [Abstract][Full Text] [Related]
16. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet; 1998 Sep; 352(9131):837-53. PubMed ID: 9742976 [TBL] [Abstract][Full Text] [Related]
17. 10-year follow-up of intensive glucose control in type 2 diabetes. Holman RR; Paul SK; Bethel MA; Matthews DR; Neil HA N Engl J Med; 2008 Oct; 359(15):1577-89. PubMed ID: 18784090 [TBL] [Abstract][Full Text] [Related]
18. The Role of Hypoglycemia in Cardiovascular Outcomes in Diabetes. Paty BW Can J Diabetes; 2015 Dec; 39 Suppl 5():S155-9. PubMed ID: 26654859 [TBL] [Abstract][Full Text] [Related]
19. [Intensive blood glucose-lowering therapy: to which extent?]. Holleman F; de Vries JH; Hoekstra JB Ned Tijdschr Geneeskd; 2008 Nov; 152(44):2381-4. PubMed ID: 19055135 [TBL] [Abstract][Full Text] [Related]
20. Oral antidiabetic agents: current role in type 2 diabetes mellitus. Krentz AJ; Bailey CJ Drugs; 2005; 65(3):385-411. PubMed ID: 15669880 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]